D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.

Trial Profile

D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Haemangioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top